The Multiple Myeloma Minimal Residual Disease Panel (MM-MRD) is comprised of a pre-mixed 6-color 8-antibody combination and two single antibody vials : CD138-BV421 and CD27-BV510. The panel is designed for the qualitative and semi-quantitative identification and discrimination of malignant and normal plasma cells by flow cytometry using BD FACSCanto™ II and/or BD FACSLyric™ Flow Cytometers. It is intended to be used for staining of bone marrow specimens of Multiple Myeloma treated patients.